DIGITALDX
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Rumi Yokota
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Erin Niehaus
      • Vivian Lu
      • Amit Goldman
      • Sushreeta Mohanty
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Maria Millan
      • Renee Ryan
      • Laura Mezey
      • Barbara Levy
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
      • Molly Martell
      • Drew Watson
      • Karim Refaey
      • Jennifer Quigley
      • Tracy I George
      • Elise Singer
      • Hoda Asmar
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Macieira-Kaufmann
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
Picture
Jerry Lanchbury, JD
Picture
  • Chief Scientific Officer — Myriad Genetics
  • Executive VP —Myriad Genetics
  • SVP Rearch — Myriad Genetics
  • Reader in Molecular Immunogenetics and Head of Molecular Genetics — GKT School of Medicine, King’s College London
  • PhD, Human Population Genetics, Newcastle University
At Myriad Genetics, Jerry Lanchbury led teams that were responsible for major molecular diagnostic innovations across the areas of oncology, urology, rheumatology and neuroscience. Proven track record in molecular genetic discovery, clinical product ideation and translation into high value clinical and companion diagnostics. Discoveries ranged across cancer prognostics, cancer genetic predisposition tests, rheumatoid arthritis disease activity and prognosis and cardiovascular disease risk prediction. Notable field transforming products included myChoice HRD for PARP inhibitors, BracAnalysis CDX for PARP inhibitors, Prolaris, myPlan Lung, myRisk, Riskscore for all ancestries, Vectra and Vectra cardiovascular. 

Prior to Myriad Genetics, Lanchbury was a Strateigeic Advisor to Gemini Genomics, Director of Dunhill Medical Research Laboratories, Senior Lecturer in Molecular Immunogenetics, Division of Medicine at United Medical and Dental Schools of Guys and St. Thomas Hospitals, and Deputy Director of Clinical Science Laboratories at United Medical and Dental Schools of Guys and St. Thomas Hospitals.
​

Jerry earned his BSC (Hons) Biology from Aston University and PhD in Human Population Genetics from Newcastle University.
Disclaimer
Terms & Conditions
Privacy Policy
Investment Inquiries
Contact
Picture
Picture
Picture
 Copyright © 2025 All Rights Reserved
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Rumi Yokota
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Erin Niehaus
      • Vivian Lu
      • Amit Goldman
      • Sushreeta Mohanty
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Maria Millan
      • Renee Ryan
      • Laura Mezey
      • Barbara Levy
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
      • Molly Martell
      • Drew Watson
      • Karim Refaey
      • Jennifer Quigley
      • Tracy I George
      • Elise Singer
      • Hoda Asmar
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Macieira-Kaufmann
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press